American Herbal Products Association (AHPA) > About Us > Committees > Cannabis Committee

Committee Meeting Minutes

Committee-Related News

AHPA expresses support for WADA scientific review of cannabis in sports

October 2021: WADA scientific review to be undertaken in 2022

The American Herbal Products Association (AHPA) provided a letter of support to the World Anti-Doping Agency (WADA) following the September 14, 2021 announcement of WADA’s Executive Committee recommendation that a scientific review of cannabis (Cannabis sativa L.) will be undertaken by the agency in 2022.

AHPA updates Proposition 65 hemp industry guidance following passage of California AB 45

October 2021: New law recognizes hemp derived products as foods, dietary supplements, and cosmetics

AHPA has published an update to its Guidance on California Proposition 65 and Hemp Products to recognize the impact of the passage of California AB 45 Industrial hemp products, which was signed into law by Governor Gavin Newsome on October 6, 2021.

AHPA submits comments to the “Cannabis Administration and Opportunity Act” Discussion Draft

September 2021: AHPA Update

On September 1, 2021, AHPA submitted comments to the Senate sponsoring offices for the “Cannabis Administration and Opportunity Act” (CAOA) Discussion Draft.

AHPA submits comments to Oregon Liquor Control Commission regarding Emergency Rule for “Adult Use Cannabis and Hemp Concentration Limits”

August 2021: AHPA Cannabis Alert

On Monday August 23, 2021, AHPA submitted comments to the Oregon Liquor Control Commission (OLCC) in response to the recent enacted Emergency Rule titled “Adult Use Cannabis and Hemp Concentration Limits.”

AHPA Board of Trustees approves two new guidance resources for the hemp industry

July 2021: Latest guidance documents developed by AHPA’s Cannabis Committee

The AHPA Board of Trustees approved two new guidance resources for the hemp industry during its meeting on Tuesday June 29, 2021. The resources are the latest guidance documents developed by AHPA’s Cannabis Committee, which was formed in 2010 to address issues related to the safe use and responsible commerce of legally-marketed products derived from Cannabis species, including products derived from hemp as legalized under the 2018 Farm Bill.

Bipartisan Legislation Introduced in U.S. Senate Would Create Regulatory Pathways for Use of Hemp-Derived CBD in Dietary Supplements and Conventional Food

May 2021 - Bill would remove restrictions for use in foods and dietary supplements

Silver Spring, MD, May 19, 2021 – Today, Senators Ron Wyden and Jeff Merkley (D-OR) and Senator Rand Paul (R-KY) introduced bipartisan legislation that would protect public health by providing legal clarity in the hemp and hemp-derived cannabidiol (CBD) product marketplace.

AHPA publishes Hemp Lexicon

Lexicon clarifies use of key botanical terms relevant to hemp

The American Herbal Products Association (AHPA) has published a Hemp Lexicon intended to support the standardization of the terminology used in the cultivation, processing, manufacturing, and labeling of hemp and products derived from hemp as defined in U.S. federal law.

Bipartisan Legislation to Regulate Hemp-Derived CBD Re-introduced in Congress

February 5, 2021: Bill directs FDA to use its authority and resources to set a clear regulatory framework for hemp and hemp derived CBD

On February 4, 2021 Representative Kurt Schrader (D-OR) and Representative Morgan Griffith (R-VA) re-introduced bipartisan legislation that would protect public health by providing legal clarity in the cannabidiol (CBD) product marketplace. Re-introduced in the 117th Congress as HR 841, the Hemp and Hemp-derived CBD Consumer Protection and Market Stabilization Act of 2021 directs the U.S. Food and Drug Administration (FDA) to use its authority and resources to set a clear regulatory framework for hemp and hemp-derived CBD and assure consumer protection.

Supplement and Hemp Industry Associations Applaud Bipartisan Legislation to Regulate Hemp-Derived CBD

September 4, 2020: Bill directs FDA to use its authority and resources to set a clear regulatory framework for hemp and hemp derived CBD

the four leading dietary supplement industry associations applaud Representative Kurt Schrader (D-OR) and Representative Morgan Griffith (R-VA), for introducing bipartisan legislation that would protect public health by providing legal clarity in the cannabidiol (CBD) product marketplace. The Hemp and Hemp derived CBD Consumer Protection and Market Stabilization Act of 2020 directs the U.S. Food and Drug Administration (FDA) to use its authority and resources to set a clear regulatory framework for hemp and hemp derived CBD and assure consumer protection.

AHPA Hemp-CBD Status Report

Updated in April 2020 to cover recent FDA and USDA actions • Log-in to download

To help the herbal products industry understand the evolving regulatory landscape for hemp and hemp-derived cannabidiol (CBD) products, AHPA has updated its free Hemp-CBD Status Report to include recent actions taken by the Food and Drug Administration (FDA) and the U.S. Department of Agriculture (USDA).
RSS
12

2022 Annual Fund Sponsors

AHPA appreciates the support of its sponsors, but does not endorse, recommend, or provide a warranty for any sponsor company, its products or services. AHPA has no responsibility for any transaction entered into with any of these companies.